Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack A Roth

Showing results (291-300 of 352) with videos related to

Pageof 36
Sort By:
Annals of Surgery|August 23, 2002
Treatment outcomes of resected esophageal cancerWayne Hofstetter, Stephen G Swisher, Arlene M Correa, et al.
International Journal of Cancer|November 28, 2002
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancerShinichi Toyooka, Riichiroh Maruyama, Kiyomi O Toyooka, et al.
Clinical Lung Cancer|October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and NeckJohn Nemunaitis, Gary Clayman, Sanjiv S Agarwala, et al.
Cancer Research|December 4, 2002
BRAF and RAS mutations in human lung cancer and melanomaMarcia S Brose, Patricia Volpe, Michael Feldman, et al.
American Journal of Cancer Research|January 8, 2021
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutationsXiaoshan Zhang, Ran Zhang, Huiqin Chen, et al.
Communications Biology|May 11, 2023
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibIsmail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Annals of Surgery|September 2, 2022
High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be DelayedErin M Bayley, Megan L Ivy, Jitesh B Shewale, et al.
Journal of Surgical Oncology|February 21, 2020
High mutational concordance between primary colorectal tumors and associated pulmonary metastasesErin M Corsini, Saumil S Datar, Kyle G Mitchell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.
Pageof 36

Showing results (291-300 of 352) with videos related to

Sort By:
Pageof 36
Annals of Surgery|August 23, 2002
Treatment outcomes of resected esophageal cancerWayne Hofstetter, Stephen G Swisher, Arlene M Correa, et al.
International Journal of Cancer|November 28, 2002
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancerShinichi Toyooka, Riichiroh Maruyama, Kiyomi O Toyooka, et al.
Clinical Lung Cancer|October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and NeckJohn Nemunaitis, Gary Clayman, Sanjiv S Agarwala, et al.
Cancer Research|December 4, 2002
BRAF and RAS mutations in human lung cancer and melanomaMarcia S Brose, Patricia Volpe, Michael Feldman, et al.
American Journal of Cancer Research|January 8, 2021
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutationsXiaoshan Zhang, Ran Zhang, Huiqin Chen, et al.
Communications Biology|May 11, 2023
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibIsmail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Annals of Surgery|September 2, 2022
High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be DelayedErin M Bayley, Megan L Ivy, Jitesh B Shewale, et al.
Journal of Surgical Oncology|February 21, 2020
High mutational concordance between primary colorectal tumors and associated pulmonary metastasesErin M Corsini, Saumil S Datar, Kyle G Mitchell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.
Pageof 36